For type 2 diabetes mellitus. ANDA 203686, held by Zydus Hlthcare. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 203686 (Metformin Hydrochloride), held by Zydus Hlthcare, was first approved by FDA on Aug 28, 2014, with 5 approved supplements and 0 published complete response letters.
Metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 28, 2014 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride850MG · tablet;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride1GM · tablet;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 19Labeling · Standard review | Approved | None posted |
| Apr 30, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 30, 2021 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 30, 2021 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 13, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 28, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters